期刊文献+

靶向溶血磷脂酸受体的小分子激动剂和拮抗剂的研究进展

Development of the small molecule agonists and antagonists targeted on LPA receptors
原文传递
导出
摘要 溶血磷脂酸(LPA)可以与多种亚型受体结合,参与诸多信号调节,产生多种病理生理反应,它与心肌肥厚、肿瘤细胞的侵袭、转移和血管生成、器官纤维化、骨关节炎、神经性疼痛、精神分裂症多种疾病相关。靶向LPA受体的激动剂和拮抗剂是目前药物化学的研究热点。本文主要介绍小分子LPA受体激动剂和拮抗剂的结构及构效关系等方面的研究进展。 Lysophosphatidic acid (LPA) and its receptors, LPA1 - LPA6, are integral parts of signaling pathways involved in cellular proliferation, migration and survival. These signaling pathways are of therapeutic interest for the treatment of multiple types of cancer and to reduce cancer metastasis and side effects. Validated therapeutic potential of key receptors, as well as recent structure-activity relationships yielding compounds are exciting recent advances in the field. This review summarizes evaluation of LPA agonists and antagonists.
出处 《中国药物化学杂志》 CAS CSCD 2017年第1期67-77,共11页 Chinese Journal of Medicinal Chemistry
基金 国家自然科学基金项目(81573343) 军队医学创新专项(13CXZ016)
关键词 溶血磷脂酸(LPA) LPA受体 拮抗剂 激动剂 构效关系 lysophosphatidic acid (LPA) LPA receptors agonists antagonists SAR
  • 相关文献

二级参考文献124

  • 1Waters CM, Long J, Gorshkova I, Fujiwara Y, Connell M, Belmonte KE, et al. Cell migration activated by platelet-derived growth factor receptor is blocked by an inverse agonist of the sphingosine 1-phosphate receptor-1. FASEB J 2006; 20:509-11.
  • 2Yonesu K, Ohnuki T, Ono Y, Takatsu T, Nara F. Ascotricins A and B, novel antagonists of sphingosine-l-phosphate receptor 1 from Ascotricha chartarum Berk. SANK 14186. J Antibiot (Tokyo) 2009; 62: 359-64.
  • 3Yonesu K, Kawase Y, Inoue T, Takagi N, Tsuchida J, Takuwa Y, et al. Involvement of sphingosine-1-phosphate and S1P1 in angiogenesis: analyses using a new S1P1 antagonist of non-sphingosine-1-phosphate analog. Biochem Pharmacol 2009; 77: 1011-20.
  • 4Goetzl E J, Dembrow D, Van Brocklyn JR, Graler M, Huang MC. An IgM- kappa rat monoclonal antibody specific for the type 1 sphingosine 1-phosphate G protein-coupled receptor with antagonist and agonist activities. Immunol Lett 2004; 93: 63-9.
  • 5Koide Y, Hasegawa T, Takahashi A, Endo A, Mochizuki N, Nakagawa M, et al. Development of novel EDG3 antagonists using a 3D database search and their structure-activity relationships. J Med Chem 2002; 45: 4629-38.
  • 6Jongsma M, Hendriks-Balk MC, Michel MC, Peters SL, Alewijnse AE. BML-241 fails to display selective antagonism at the sphingosine-1- phosphate receptor, S1P3- Br J Pharmacol 2006; 149: 277-82.
  • 7Koide Y, Uemoto K, Hasegawa T, Sada T, Murakami A, Takasugi H, et al. Pharmacophore-based design of sphingosine 1-phosphate-3 receptor antagonists that include a 3,4-dialkoxybenzophenone scaffold. J Med Chem 2007; 50: 442-54.
  • 8Zhang H, Desai NN, Olivera A, Seki T, Brooker G, Spiegel S. Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol 1991; 114: 155-67.
  • 9Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009; 78: 743- 68.
  • 10Rivera R, Chun J. Biological effects of lysophospholipids. Rev Physiol Biochem Pharmaco12008; 160: 25-46.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部